PharmaDrug's Super Smart Launches Online Retail Platform in the United States
Toronto, Ontario--(Newsfile Corp. - May 17, 2021) - PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company") a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that its Super Smart division has launched a Slim Winkel branded online retail platform in the U.S. that will focus on functional...
2021-05-17 7:49 AM EDT
PharmaDrug Signs Supply Agreement with European Cannabis Extractor for Medical Grade THC Oil to Be Sold Under PharmaDrug Brand
Toronto, Ontario--(Newsfile Corp. - May 14, 2021) - PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company") a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that it has entered into a supply agreement (the "Supply Agreement") with an emerging Eurozone cannabis extractor for medical grade...
2021-05-14 9:25 AM EDT
PharmaDrug Enters into Employment Agreement with Dr. Paul Van Slyke and Grants Him Options and Promotes Him to Chief Scientific Officer for All of Pharmadrug
Toronto, Ontario--(Newsfile Corp. - May 13, 2021) - PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that it has entered into an employment agreement with Dr. Paul Van Slyke and promoted him to Chief Scientific Officer (CSO) for all...
2021-05-13 8:00 AM EDT
PharmaDrug Initiates Preclinical Study of Cepharanthine to Both Broaden Its Cancer Scope and to Streamline Its Strategy for Esophageal Cancer
Toronto, Ontario--(Newsfile Corp. - May 6, 2021) - PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that it has entered into a service agreement with a respected contract research organization (CRO) with deep expertise in preclinical...
2021-05-06 9:26 AM EDT
PharmaDrug Announces First FDA Orphan Drug Designation of DMT for the Prevention of Ischemia-Reperfusion Injury from Organ Transplantation
Toronto, Ontario--(Newsfile Corp. - April 28, 2021) - PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that the U.S. Food and Drug Administration ("FDA") has granted Orphan Drug Designation ("ODD") to dimethyltryptamine ("DMT") for...
2021-04-28 8:03 AM EDT
PharmaDrug Advances Product and Clinical Development of Cepharanthine to Treat Rare Cancers and Infectious Diseases
Toronto, Ontario--(Newsfile Corp. - April 20, 2021) - PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that the Company has entered into an agreement with Southwest Research Institute® ("SwRI®"), to initiate non-clinical and clinical...
2021-04-20 7:30 AM EDT
Pharmadrug Initiates DMT Research Activities via Collaboration with the University of Michigan for Foundational DMT Research Study
Toronto, Ontario--(Newsfile Corp. - March 16, 2021) - PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that the Company has entered into a sponsored research agreement with the University of Michigan, under the direction of Dr. Jimo...
2021-03-16 8:00 AM EDT
PharmaDrug Provides Update on Its Annual General Meeting
Toronto, Ontario--(Newsfile Corp. - March 12, 2021) - PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), will hold its Annual General Meeting ("AGM" or "Meeting") on March 25, 2021 at 10:00AM Eastern Standard Time at its corporate office, Suite 2905 - 77 King Street West, Toronto. The call-in number for the Meeting is 1-855-473-1059 and the access # 0091269. In light of the ongoing COVID-19 situation, the Company strongly encourages registered shareholders and...
2021-03-12 5:08 PM EST
PharmaDrug Announces Drug-Repurposing Expert Moshe Rogosnitzky Joins Sairiyo Therapeutics Scientific and Clinical Advisory Board
Toronto, Ontario--(Newsfile Corp. - March 9, 2021) - PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company") wholly-owned subsidiary, Sairiyo Therapeutics Inc. ("Sairiyo"), a biotechnology company focused on the research and development of Cepharanthine, a repurposed and reformulated naturally-derived compound for the potential treatment of cancer, neurological, inflammatory and infectious diseases, is pleased to announce that world-renowned drug-repurposing expert,...
2021-03-09 8:00 AM EST
PharmaDrug Announces World-Renowned Gastric Cancer Expert Dr. Yelena Y. Janjigian Joins Sairiyo Therapeutics Scientific and Clinical Advisory Board
Toronto, Ontario--(Newsfile Corp. - March 4, 2021) - PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company") wholly-owned subsidiary, Sariyo Therapeutics Inc. ("Sairiyo"), a biotechnology company focused on the research and development of Cepharanthine, a repurposed and reformulated naturally-derived compound for the potential treatment of cancer, neurological, inflammatory and infectious diseases, is pleased to announce that world-renowned gastric cancer expert, Dr....
2021-03-04 8:00 AM EST
PharmaDrug Files For FDA Orphan Drug Designation For DMT In Kidney Transplantation and Expands on Its Psychedelics Strategy
Toronto, Ontario--(Newsfile Corp. - February 25, 2021) - PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce it has expanded its psychedelic pharmaceutical program with the filing of an application with the U.S. Food and Drug...
2021-02-25 7:33 AM EST
PharmaDrug Files for FDA Orphan Drug Designation for DMT in Stroke
Toronto, Ontario--(Newsfile Corp. - February 11, 2021) - PharmaDrug Inc. (CSE: BUZZ) (OTC: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances, natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce it has filed an application with the U.S. Food and Drug Administration ("FDA") to receive Orphan Drug Designation ("ODD") for...
2021-02-11 8:13 AM EST
PharmaDrug Appoints World-Renowned DMT Expert Dr. Steven A. Barker to Its Scientific Advisory Board for Psychedelic Pharmaceuticals
Toronto, Ontario--(Newsfile Corp. - February 8, 2021) - PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that is has appointed world-renowned chemist and neuroscientist Dr. Steven A. Barker, Ph.D. to the Company's newly-formed...
2021-02-08 7:00 AM EST
PharmaDrug Grants Stock Options
Toronto, Ontario--(Newsfile Corp. - February 5, 2021) - PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company") announces the grant of stock options to directors, officers and consultants to purchase 5,200,000 common shares of the Company, exercisable at $0.085 per share at any time on or before February 4, 2026. The grants are subject to the terms of the Company's stock option plan. In accordance with regulatory requirements, any shares issued pursuant to the exercise...
2021-02-05 4:30 PM EST
PharmaDrug Signs Supply Agreement with Global Cannabis Supplier and Provides Update on German Operations and Balance Sheet Improvements
Toronto, Ontario--(Newsfile Corp. - February 4, 2021) - PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company") has entered into a supply agreement (the "Supply Agreement") on January 4, 2021, with a Canadian based multinational cannabis company for EU-GMP certified medical cannabis. The supply is already registered and approved for sale in the German market.Pursuant to the Supply Agreement, the Company's licensed German distributor, Pharmadrug Production GmbH...
2021-02-04 8:23 AM EST
PharmaDrug Completes Acquisition of Sairiyo Therapeutics Inc.
Toronto, Ontario--(Newsfile Corp. - February 2, 2021) - PharmaDrug Inc. (CSE: BUZZ) (OTC: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, today announced that it has completed the previously announced (see press releases dated January 12, 2021 and January 25, 2021) acquisition of Sairiyo Therapeutics...
2021-02-02 8:39 AM EST
PharmaDrug Enters Definitive Agreement for Acquisition of Sairiyo Therapeutics Inc. Who Recently Received Orphan Drug Designation from FDA for Esophageal Cancer
Toronto, Ontario--(Newsfile Corp. - January 25, 2021) - PharmaDrug Inc. (CSE: BUZZ) (OTC: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, today announced that it has entered into the definitive agreement in respect of the previously announced (see press release dated January 12, 2021) proposed...
2021-01-25 8:19 AM EST
PharmaDrug Announces LOI to Acquire Sairiyo Therapeutics Inc.
Toronto, Ontario--(Newsfile Corp. - January 12, 2021) - PharmaDrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company"), a specialty pharmaceutical company focused on the development and commercialization of controlled-substances and natural medicines such as psychedelics, cannabis and naturally-derived approved drugs, is pleased to announce that it has entered into a binding letter of intent (the "LOI"), dated January 11, 2021, to acquire Sairiyo Therapeutics Inc. ("Sairiyo")...
2021-01-12 8:00 AM EST
Pharmadrug Provides Corporate Update and Balance Sheet Status
Toronto, Ontario--(Newsfile Corp. - December 15, 2020) - Pharmadrug Inc. (CSE: BUZZ) (OTC Pink: LMLLF) ("PharmaDrug" or the "Company") is pleased to provide an update to the status of its balance sheet following the recent general equity market upswing and the increase in PharmaDrug's volume and share price appreciation. Recent market activity has served to significantly strengthen PharmaDrug's balance sheet and improve its ability to execute on its current business plan. The market has...
2020-12-15 8:38 AM EST
Pharmadrug Shortlists Prime Amsterdam Locations for State-of-the-art Smart Shop Superstore and Expands Scope of E-Commerce Platform with Essential Good
Toronto, Ontario--(Newsfile Corp. - November 30, 2020) - Pharmadrug Inc. (CSE: BUZZ) (OTC: LMLLF) ("PharmaDrug" or the "Company") is pleased to announce that its wholly-owned subsidiary Interrobang Ltd. (doing business as Super Smart) ("Super Smart") will be launching its new Slim Winkel brand in the next couple of weeks. The Company's work with Essential Good LLC ("Essential Good") has advanced tremendously and the Company expects the new online retail store will be ready to launch early in...
2020-11-30 9:08 AM EST